论文部分内容阅读
目的:HER2(human EGF receptor type 2)在食管癌中的过表达是否与食管癌患者生存期缩短相关,存在着两种不同的观点。为此,我们在大样本回顾性调查基础上,做进一步的研究,为弄清两者是否相关提供有用的数据资料。方法:在收集1988~1997年间的341例食管癌病例进行回顾性调查的基础上,通过联合应用组织芯片和免疫组织化学等实验方法检测食管癌组织中HER2的表达,分析HER2表达与食管癌患者生存期之间的相关性。结果:与正常食管上皮组织相比,HER2在多数食管癌组织中过表达;HER2过表达与食管癌组织细胞的分化程度相关(P<0.05);但与食管癌患者生存期缩短相关性不明显(P>0.05)。结论:按FDA判定标准,食管癌组织细胞中HER2蛋白的过表达不是判定食管癌患者生存期缩短的有效指标。
OBJECTIVE: Whether HER2 (human EGF receptor type 2) overexpression in esophageal cancer is related to the shortened survival of patients with esophageal cancer exists in two different perspectives. To this end, based on a large sample of retrospective surveys, we conducted further studies to provide useful data to understand whether the two are relevant. Methods: Based on a retrospective survey of 341 cases of esophageal cancer collected from 1988 to 1997, the expression of HER2 in esophageal cancer tissues was detected by the combination of tissue microarray and immunohistochemistry. The expression of HER2 in esophageal cancer patients Relevance of survival. Results: Compared with normal esophageal epithelium, HER2 was overexpressed in most esophageal cancer tissues. The overexpression of HER2 was associated with the differentiation of esophageal cancer cells (P <0.05), but not correlated with the shortened survival of esophageal cancer patients (P> 0.05). Conclusion: The overexpression of HER2 protein in esophageal cancer cells is not an effective measure to determine the shortened survival of patients with esophageal cancer according to FDA standards.